NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
1월 13 게시
The NVIDIA-Eli Lilly $1 billion partnership is already setting new industry standards, potentially triggering a wave of similar high-value collaborations across the sector.
These companies are at the forefront of using artificial intelligence to solve healthcare's biggest challenges, from drug discovery to personalised treatments.
Early investors in AI-powered healthcare could benefit as this technology transforms how we develop medicines and treat diseases worldwide.
The $1 billion NVIDIA and Eli Lilly partnership marks a pivotal moment where artificial intelligence meets pharmaceutical innovation. This collaboration signals that AI is becoming fundamental to modern drug discovery, creating opportunities for companies that can harness computational power to accelerate medical breakthroughs and transform healthcare outcomes.
This group spans from technology giants providing AI infrastructure to biotech innovators using machine learning for drug development. These companies represent a high-growth sector where computational biology, precision medicine, and automated analysis are revolutionising how we discover and develop new treatments for complex diseases.
Each company has been handpicked by professional analysts for their strategic position at the intersection of AI and healthcare. They range from established pharmaceutical leaders actively investing in AI capabilities to emerging specialists using proprietary platforms to solve complex therapeutic challenges through computational innovation.
This basket's total market cap is 5,994,886.71147 and its value is heavily concentrated in a few very large-cap holdings that anchor the portfolio. Roughly 92% of the total market cap sits in the two largest positions, indicating a top-heavy weighting that tends to reduce volatility but limits diversification.
NVDA: $4.49T
LLY: $1.02T
REGN: $80.72B
이 바스켓의 전체 스토리를 확인하세요. 리스크와 잠재력을 다룬 상세 기사를 읽어보세요.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+7
Here are a few of the assets in this group. Create an account to unlock the full list.
REGENERON PHARMACEUTICALS INC
REGN
현재가
$781.49
Regeneron utilises its proprietary VelociSuite technologies, which integrate large-scale genetic data and automation, aligning with AI-driven approach...
Regeneron utilises its proprietary VelociSuite technologies, which integrate large-scale genetic data and automation, aligning with AI-driven approaches to accelerate drug development.
Join Nemo FREE today and unlock every stock
60초면 충분합니다.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
이 자산들에 투자했다면:
12개월 후 예상 가치:
+126.88%
애널리스트들은 이 그룹의 자산이 향후 1년간 평균 126.88% 성장할 것으로 예상합니다.
이 그룹의 자산 16개 중 15개가 전문 애널리스트로부터 매수 의견을 받았습니다.
